全球肺癌治療市場

Abstract

This report analyzes the worldwide markets (Annual Revenues) for Lung Cancer Therapeutics in Millions of US$. The US market for Non-Small Cell Lung Cancer treatment is further analyzed by: Chemotherapy Drugs, and Targeted Drugs. The report provides separate comprehensive analytics for the US, Europe and Rest of World. Annual forecasts are provided for each region for the period 2005 through 2015. The report profiles 191 companies including many key and niche players worldwide such as AstraZeneca PLC., Bristol-Myers Squibb Co., Eli Lilly & Co., F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline Plc., Novartis Pharmaceuticals Corporation, OSI Pharmaceuticals, Inc., Sanofi-Aventis, AbGenomics International Inc., ImClone Systems, Inc., Pfizer, Inc., Merck Serono International S.A., Merck & Co. Ltd., Telik, Inc., and Woomera Therapeutics, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

• Study Reliability and Reporting Limitations
• Disclaimers
• Data Interpretation & Reporting Level
• Quantitative Techniques & Analytics
• Product Definitions and Scope of Study
• Chemotherapy Drugs
• Targeted Drugs

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

• Lung Cancer Therapeutics - Driven by Next Generation Drugs
• New Therapies Drive NSCLC Market
• Market Value of Taxanes to Decrease by 2015
• Lung Cancer - The Killer Disease
• Lung Cancer - A Quick Glance at Global Statistics
• Asia Heading for Possible Lung Cancer Epidemic
• Table 1: Global Incidence of Lung Cancer (2008): Percentage Share Breakdown by Region (includes corresponding Graph/Chart)

2. LUNG CANCER - AN INSIGHT

• Lungs - Critical for Oxygen Supply
• Lung Cancer - An Introduction
• Common Symptoms of Lung Cancer
• Types of Lung Cancer
• Non-Small Cell Lung Cancer
• NSCLC - At a Glance
• Small Cell Lung Cancer
• Risk Factors for Lung Cancer
• Female Smokers at Higher Risk of Developing Lung Cancer
• Lung Cancer Diagnostics
• Lung Cancer Staging
• Staging for Non-Small Cell Lung Cancer
• Staging for Small Cell Lung Cancer

3. LUNG CANCER TREATMENT MODALITIES

• Surgery
• Radiation Therapy
• Chemotherapy
• Combination Therapy
• Photodynamic Therapy
• Vaccines
• Common Treatment Modalities for SCLC and NSCLC Lung Cancers
• Pain Management

4. INTRODUCTION TO LUNG CANCER THERAPEUTICS

• Chemotherapy
• Drug Administration
• Overview of Chemotherapy Regimens and Drugs
• Side Effects of Chemotherapy
• Targeted Therapy
• Chemotherapy Drugs for SCLC Treatment
• Chemotherapy Drugs for NSCLC Treatment
• Major Chemotherapy Drugs
• Select Chemotherapy Drugs Used in the Treatment of Lung Cancer by Brand and Generic Name
• Overview of Select Chemotherapeutic Drugs
• Alimta
• Carboplatin and Cisplatin
• Docetaxel
• Paclitaxel
• Xyotax
• Gemcitabine
• Gefitinib
• Irinotecan
• Vinorelbine (Navelbine(r))

5. PRODUCT DEVELOPMENT IN NSCLC THERAPEUTICS

• R&D Focus in NSCLC Treatment
• Drug Development Process - Growth Opportunities & Challenges
• Product Pipeline for NSCLC Treatment
• Product Pipeline for NSCLC Treatment
• Select (Ongoing/Completed) Clinical Trials for NSCLC Treatment
• Companies Focus on Molecular Targeted Therapies
• Molecular Targeted Therapies - Overview of Select Product Candidates
• Aflibercept (VEGF-Trap) - Sanofi Aventis/ Regeneron
• BIBW 2992 - Boehringer Ingelheim
• Erbitux (cetuximab) - ImClone/Merck Serono/Bristol- Myers Squibb
• Nexavar (sorafenib) - Bayer Schering
• Recentin (cediranib) - AstraZeneca
• Sutent (sunitinib) - Pfizer
• Zactima (vandetanib) - AstraZeneca
• Zolinza (vorinostat) - Merck & Co
• Pipeline for Cytotoxic Therapy - Overview of Select Products
• Abraxane (albumin-bound paclitaxel) - Abraxis
• Glutoxim (NOV-002) - Novelos
• Javlor (vinflunine) - Pierre Fabre
• Lipoplatin (liposomal cisplatin) - Regulon
• Xyotax (paclitaxel polyglumex) - Cell Therapeutics/ Novartis

6. PRODUCT APPROVALS/INNOVATIONS/LAUNCHES

• Intas Biopharmaceuticals to Introduce Gefitinib in India
• Celgene Receives FDA Fast Track Product Designation for Amrubicin
• EMEA Approves ALIMTA for First-Line Therapy of Advanced NSCLC
• Celgene' s Cancer Drug Receives Orphan Drug Status from European Commission
• Alimta Receives FDA Approval
• Roche Receives Approval from European Authorities for Avastin
• OSI Pharmaceuticals Introduces Tarceva in Japan
• Shanghai Medipharm Introduces TNT Antibody for Treating Lung Cancer
• Natco Pharma Unveils an Injectible Drug for Lung Cancer, Pemnat
• Roche Scientific Introduces Tarceva in the Indian Market
• GlaxoSmithKline' s HYCAMTIN(r) Receives Marketing Approval from EC
• Genzyme Launches New Genetic Mutation Test to Aid Lung Cancer Treatment
• UT Southwestern Medical Center Researchers Discover New Anti-Cancer Drug
• Agennix' s Talactoferrin Alfa Program Obtains Fast Track Designation from FDA
• Novelos Therapeutics' NOV-002 Receives Fast Track Designation from FDA

7. RESEARCH & CLINICAL TRIALS

• Novartis Commences Phase III Clinical Trial of ASA404
• Results of BR.21 Trials
• Genentech Announces Results of Phase III BETA Lung Trial
• Results of SATURN Clinical Trial
• Results of Zactima' s Clinical Trials
• Results of Erbitux' s Phase III Trials
• Results of Roche' s AVAiL Clinical Trial
• GlaxoSmithKline Conducts Phase III Clinical Trial of Lung Cancer Vaccine
• FASgen Announces Research Results of FAS093
• The Cuban Regulatory Agency Registers a New Therapeutic Lung Cancer Vaccine
• Gemin X Commences Clinical Trials of GX15-070
• Antisoma and Biomira Announce Clinical Trial Results of Lung Cancer Drugs
• OSI Pharmaceuticals Commences Phase III Clinical Trials of Tarceva(r)
• Northwest Gets FDA Clearance to Conduct Clinical Trials for Lung Cancer Vaccine
• University of Kentucky Conducts Clinical Trials on Lung Cancer Vaccine
• Poniard Enrolls in Phase II Small Cell Lung Cancer Clinical Trials of Picoplatin
• Sunesis Pharmaceuticals Starts Phase II Clinical Trials of SNS-595
• Ligand Pharmaceuticals Tables Clinical Results of Targretin(r)
• Bayer and Onyx Start Phase III Trial of Nexavar(r)
• Abraxis Announces Clinical Results of ABRAXANE(r)
• Introgen Conducts Phase II Clinical Trials of INGN 225
• YM BioSciences Commences Clinical Trial of Nimotuzumab

8. RECENT INDUSTRY ACTIVITY

• Merck Agrees to Merge with Shering-Plough
• Abbott Molecular Signs Agreement with Genentech, OSI and Roche
• IMUC Acquires Monoclonal Antibody Technology from MDC
• Quest PharmaTech Enters into Collaboration with BC Cancer Agency
• Daiichi Sankyo Acquires U3 Pharma
• MacroGenics Takes Over Raven Biotechnologies
• Roche Acquires Piramed
• Bristol-Myers Squibb Acquires Kosan Biosciences
• Point Therapeutics and DARA Biosciences Ink Merger Agreement
• Celgene Acquires Pharmion
• Pfizer to Takeover Serenex
• ATS Acquires Majority Stake in GANYMED Pharmaceuticals
• NCCN, AstraZeneca and Abraxis Enter into Collaboration
• Eli Lilly Agrees to Take Over ImClone Systems
• CytRx Takes Over Innovive Pharmaceuticals
• Abbott Extends Discovery Partnership with Caprion
• Bristol-Myers and ImClone to Expand the Clinical Development Program for ERBITUX
• Biomoda and New Mexico Tech Enter into a Collaborative Agreement
• Binex Inks Sponsored Research Agreement with MaxCyte
• Simcere Pharmaceutical Acquires Master Luck
• Dako Enters into Collaboration with OSI, Roche, and Genentech
• Biomira and Merck Sign Revised Supply and Collaboration Agreements
• ImClone Systems Terminates Development Agreement with UCB
• Astellas Pharma' s US Subsidiary Acquires Agensys
• Antisoma Enters into an Agreement with Novartis
• Pharmacyclics Files NDA for Xcytrin(r) Injection

9. FOCUS ON SELECT GLOBAL PLAYERS

• AstraZeneca PLC (UK)
• Bristol-Myers Squibb Co. (US)
• Eli Lilly & Co. (US)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Genentech, Inc. (US)
• GlaxoSmithKline Plc (UK)
• Novartis Pharmaceuticals Corporation (US)
• OSI Pharmaceuticals, Inc. (US)
• Sanofi-Aventis (France)
• Companies with Pipeline Drugs
• AbGenomics International Inc. (US)
• ImClone Systems, Inc. (US)
• Pfizer, Inc. (US)
• Merck Serono International S.A. (Switzerland)
• Merck & Co. Ltd. (US)
• Telik, Inc. (US)
• Woomera Therapeutics, Inc. (US)

10. GLOBAL MARKET PERSPECTIVE

• Table 2: World Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market by Geographic Region - US, Europe and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)
• Table 3: World 10-Year Perspective for Non-Small Cell Lung Cancer Therapeutics by Geographic Region - Percentage Breakdown of Annual Revenues for US, Europe and Rest of World Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

• A. Market Analysis
• NSCLC Drug Market to Rise Sharply
• Lung Cancer Prevalence
• A Major Cause of Death among US Women
• Statistics
• Market Scenario
• FDA Places New Restrictions on Iressa
• Innovative Technology Enables Early Diagnosis of Lung Cancer
• Avastin to Emerge as the Preferred NSCLC Drug in the US
• Product Approvals/Clinical Trials/Introductions/ Launches
• Strategic Corporate Developments
• Key Players
• B. Market Analytics
• Table 4: US Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics by Segment - Chemotherapy Drugs and Targeted Drugs Markets Independently Analyzed with Annual Revenues in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)
• Table 5: US 10-Year Perspective for Non-Small Cell Lung Cancer Therapeutics by Segment - Percentage Breakdown of Annual Revenues for Chemotherapy Drugs and Targeted Drugs Markets for Years 2006, 2009 & 2015

2. EUROPE

• A. Market Analysis
• Lung Cancer Therapeutics Market to Witness Robust Growth
• Product Approvals
• Clinical Trials
• B. Market Analytics
• Table 6: European Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Independently Analyzed with Annual Revenues in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)
• Table 7: European 10-Year Perspective for Non-Small Cell Lung Cancer Therapeutics Market by Geographic Region - Percentage Breakdown of Annual Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)

2a. FRANCE

• A. Market Analysis
• Overview of Lung Cancer Market
• Key Player
• B. Market Analytics
• Table 8: French Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)

2b. GERMANY

• A. Market Analysis
• Lung Cancer Scenario
• Chemotherapy Gains Preference
• Strategic Corporate Developments
• B. Market Analytics
• Table 9: German Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)

2c. ITALY

• A. Market Analysis
• Incidence in Women on Rise
• Treatment
• B. Market Analytics
• Table 10: Italian Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)

2d. THE UNITED KINGDOM

• A. Market Analysis
• British Women at Higher Risk
• Fast Facts
• Proposed Cancer Care Improvements Mulled by British Government
• NICE Recommends Use of Erlotinib in NSCLC Treatment
• Strategic Corporate Developments
• Key Players
• B. Market Analytics
• Table 11: UK Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)

2e. REST OF EUROPE

• A. Market Analysis
• Outlook
• Strategic Corporate Developments
• Key Player
• B. Market Analytics
• Table 12: Rest of Europe Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)

3. REST OF WORLD

• A. Market Analysis
• Australia
• Fast Facts
• Brazil
• China
• Overview of NSCLC Drug Market
• India
• Japan
• Product Launches
• Strategic Corporate Development
• B. Market Analytics
• Table 13: Rest of World Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE